Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine. Eighteen of 30 patients (60%) showed objective regressions, including ten complete responses (33%). Responders had cutaneous, nodal, and/or pulmonary involvement, but objective regressions were not achieved in patients with hepatic or brain metastases. The median response duration was 8 months and the median survival of the responders was 20 months compared to 5 months for nonresponders. These promising preliminary results require confirmation.
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008130:Lomustine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage*; D010865:Pilot Projects; D011344:Procarbazine / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage*
D009607:Nitrosourea Compounds; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine